Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
In his new role as Managing Director India and Global Head, Partnerships and Innovative Finance, Singh will oversee the financial, human, and operational functions of the India office
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
It is used for the treatment of advanced colorectal and gastric cancer
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
Subscribe To Our Newsletter & Stay Updated
